Royalty Pharma plcRPRX
Price$57.63Intrinsic value$38.6633% below price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $38.66median of 6 methods · middle span $35-$57based on filings through 30 Jun 2026
Market Price $57.63Price as of 1 Oct 2026
Margin of Safety -32.9%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 11.3% (near-term consensus, capped) · years 2–5: 10.0%/yr (balance of the path).10.3% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 69.2%Yr 78.5%Yr 87.7%Yr 96.9%Yr 106.2%
10.0% → 6.2%
Years 11–20: glide to long-run rate
Per-year rates
Yr 115.8%Yr 125.5%Yr 135.2%Yr 144.9%Yr 154.6%Yr 164.3%Yr 173.9%Yr 183.6%Yr 193.3%Yr 203.0%
6.2% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 1 window (5y) (limited history)6.2%
Discount rate (cost of equity) 7.7%
Volatility vs market (adjusted beta)0.62

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetRoyalty Pharma plcRPRXHealth Care
Valuation
P/E31.0×
P/S13.4×
P/B3.3×
EV / Revenue16.6×
EV / EBITDA—
Profitability
Gross margin100.0%
Operating margin89.3%
Net margin32.0%
FCF margin—
Returns
ROE8.3%
ROA4.1%
ROIC4.5%
Growth
Revenue growth (YoY)12.0%
5-yr fwd EPS growth10.3%
Financial strength
Debt / Equity0.92×
Current ratio2.80×
Altman Z-Score2.6
Interest coverage—
Dividend yield0.8%

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.